Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on January 8, 2024. The company is headquartered in Bothell, Washington, and its common stock trades on The Nasdaq Capital Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely as a disclosure of a corporate presentation.
Material Changes
No material changes to financial condition or operations are reported in this filing. The report discloses that the Company made a presentation to the investment community on January 8, 2024.
Guidance, Outlook, and Risks
The filing references a corporate presentation (Exhibit 99.1) provided to investors. The text explicitly states that the information in this Item 7.01 and the accompanying presentation is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under such section. Consequently, no specific guidance, outlook, or risk factors are detailed within the body of this 8-K text.
Key Facts for Investor Verification
- Verify the content of the corporate presentation dated January 8, 2024, by reviewing Exhibit 99.1 attached to the full filing.
- Note that the presentation materials are not legally "filed" and do not carry the same liability protections as standard SEC filings.
- Confirm the company's current financial status through its most recent 10-K or 10-Q, as this 8-K contains no financial data.